Physician
Nicholas R Halper MD PC
Nicholas R Halper MD PC was paid $3.28M by Medicaid between Jan 2018 and Dec 2024, across 126 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 27% of everything it billed.
33Billing provider infoNICHOLAS R HALPER MD PC
ROCKVILLE CENTRE, NY 11570
ROCKVILLE CENTRE, NY 11570
33aNPI1689691594assigned 07/16/2006
33bProvider typeFamily Medicine Physician
28Total paid$3.28M
24GClaims264,100
24DCodes billed126
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in New York
Rank by total paid#50 of 2,605
Median peer was paid$10K
This provider vs. median325×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 3,473 | $57K | |
| 2019 | 12,512 | $107K | |
| 2020 | 23,549 | $230K | |
| 2021 | 52,607 | $283K | |
| 2022 | 63,720 | $860K | |
| 2023 | 54,614 | $874K | |
| 2024incomplete | 53,625 | $868K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 27% | 22,769 | 19,059 | $885K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 11% | 5,992 | 5,588 | $369K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 5.2% | 7,091 | 6,304 | $171K |
| 99401 | 4.4% | 8,237 | 7,263 | $144K | |
| 94010 | 2.9% | 4,586 | 4,577 | $94K | |
| 99497 | 2.4% | 1,745 | 1,737 | $79K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.4% | 3,487 | 3,269 | $78K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 2.4% | 1,389 | 1,385 | $77K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 2.2% | 1,088 | 1,086 | $73K |
| 93000 | 2.2% | 5,768 | 5,712 | $71K | |
| 92557 | 2.1% | 3,330 | 3,326 | $69K | |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 2.0% | 1,325 | 1,320 | $67K |
114 more codes
| 99385 | 1.7% | 827 | $55K | |
| 83970 | 1.6% | 2,647 | $53K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.4% | 264 | $45K |
| 92587 | 1.4% | 2,140 | $44K | |
| 92570 | 1.3% | 2,607 | $41K | |
| 82670 | 1.2% | 2,969 | $38K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 1.2% | 562 | $38K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.1% | 3,056 | $37K |
| G0447 | Face-to-face behavioral counseling for obesity, 15 minutes | 1.1% | 4,705 | $35K |
| 82627 | <1% | 2,874 | $30K | |
| 82607 | <1% | 4,350 | $29K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 702 | $28K |
| 82728 | <1% | 4,237 | $28K | |
| 82746 | <1% | 4,241 | $28K | |
| 86141 | <1% | 4,601 | $26K | |
| 86769 | <1% | 1,118 | $25K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,729 | $24K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 953 | $23K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 457 | $21K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 373 | $21K |
| G0442 | Annual alcohol misuse screening, 5 to 15 minutes | <1% | 3,845 | $21K |
| 80061 | Lipid panel | <1% | 4,603 | $21K |
| 80050 | General health panel | <1% | 1,574 | $20K |
| 84480 | <1% | 4,447 | $20K | |
| 84439 | <1% | 4,451 | $20K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 2,347 | $17K |
| 80053 | Comprehensive metabolic panel | <1% | 2,811 | $16K |
| 84144 | <1% | 1,592 | $15K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,519 | $15K |
| 83002 | <1% | 1,919 | $15K | |
| 83001 | <1% | 1,923 | $15K | |
| 84403 | <1% | 1,195 | $15K | |
| 84146 | <1% | 1,525 | $14K | |
| 83550 | <1% | 4,273 | $14K | |
| 83735 | <1% | 4,804 | $13K | |
| 83540 | <1% | 4,279 | $12K | |
| 99386 | <1% | 116 | $11K | |
| 84100 | <1% | 4,833 | $11K | |
| 84550 | <1% | 4,819 | $11K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 298 | $9K |
| 3074F | <1% | 6,530 | $7K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,752 | $7K |
| 81002 | <1% | 9,718 | $7K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 894 | $7K |
| 82785 | <1% | 954 | $7K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,747 | $6K |
| 83721 | <1% | 4,195 | $6K | |
| 99406 | <1% | 599 | $6K | |
| 99408 | <1% | 895 | $6K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 547 | $5K |
| 3078F | <1% | 5,200 | $5K | |
| 94060 | <1% | 142 | $5K | |
| 80074 | <1% | 350 | $5K | |
| 86328 | <1% | 275 | $5K | |
| 84153 | <1% | 579 | $5K | |
| 84270 | <1% | 1,135 | $4K | |
| 90674 | <1% | 210 | $4K | |
| 3079F | <1% | 3,334 | $3K | |
| 96127 | <1% | 2,078 | $3K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 78 | $2K |
| 82977 | <1% | 592 | $2K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 175 | $2K |
| 83615 | <1% | 601 | $2K | |
| 90756 | <1% | 107 | $2K | |
| 3075F | <1% | 1,580 | $2K | |
| 81005 | <1% | 2,105 | $2K | |
| 99173 | <1% | 2,197 | $1K | |
| 82784 | <1% | 360 | $958.28 | |
| 3077F | <1% | 1,099 | $876.50 | |
| 3080F | <1% | 748 | $740.95 | |
| 99201 | <1% | 22 | $543.53 | |
| 82948 | <1% | 385 | $521.24 | |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 98 | $469.96 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 78 | $425.00 |
| 0001A | <1% | 17 | $420.15 | |
| 87640 | <1% | 17 | $344.93 | |
| 87500 | <1% | 31 | $344.93 | |
| 87653 | <1% | 30 | $344.93 | |
| 87641 | <1% | 31 | $344.93 | |
| 81000 | <1% | 207 | $327.44 | |
| 82247 | <1% | 2,847 | $301.16 | |
| 3008F | <1% | 5,201 | $189.00 | |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | <1% | 7,658 | $185.50 |
| 86160 | <1% | 75 | $162.58 | |
| 1159F | <1% | 3,230 | $135.50 | |
| 1160F | <1% | 3,111 | $125.50 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 82 | $105.95 |
| G0446 | Annual, face-to-face intensive behavioral therapy for cardiovascular disease, individual, 15 minutes | <1% | 63 | $103.75 |
| 3044F | <1% | 621 | $89.99 | |
| G0443 | Brief face-to-face behavioral counseling for alcohol misuse, 15 minutes | <1% | 34 | $88.26 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 16 | $87.00 |
| 82248 | <1% | 21 | $82.09 | |
| 1036F | <1% | 3,217 | $70.00 | |
| 99051 | <1% | 30 | $68.43 | |
| 87486 | <1% | 12 | $60.33 | |
| 87581 | <1% | 12 | $60.33 | |
| 4004F | <1% | 393 | $42.00 | |
| 2023F | <1% | 21 | $3.50 | |
| 1111F | 0% | 16 | $0.00 | |
| 1000F | 0% | 94 | $0.00 | |
| 1125F | 0% | 205 | $0.00 | |
| 3011F | 0% | 299 | $0.00 | |
| 99050 | 0% | 38 | $0.00 | |
| 87498 | 0% | 14 | $0.00 | |
| G8430 | Documentation of a medical reason(s) for not documenting, updating, or reviewing the patient's current medications list (e.g., patient is in an acute health crisis where time is of the essence and delay of treatment would jeopardize the patient's health status) | 0% | 372 | $0.00 |
| 99070 | 0% | 48 | $0.00 | |
| 1126F | 0% | 434 | $0.00 | |
| 3048F | 0% | 96 | $0.00 | |
| G8428 | Current list of medications not documented as obtained, updated, or reviewed by the eligible clinician, reason not given | 0% | 136 | $0.00 |
| 3049F | 0% | 78 | $0.00 | |
| 99000 | 0% | 79 | $0.00 | |
| 3725F | 0% | 307 | $0.00 | |
| 3288F | 0% | 137 | $0.00 | |
| 4013F | 0% | 19 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPAWA, MUNEERA (BILLING)